Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 1
2005 4
2006 3
2008 2
2009 5
2010 5
2011 5
2012 2
2013 1
2014 1
2015 1
2016 1
2017 1
2018 1
2020 3
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
Braun S, McSheehy P, Litherland K, McKernan P, Forster-Gross N, Bachmann F, El-Shemerly M, Dimova-Dobreva M, Polyakova I, Häckl M, Zhou P, Lane H, Kellenberger L, Engelhardt M. Braun S, et al. Among authors: mcsheehy p. Expert Opin Investig Drugs. 2021 Nov;30(11):1071-1080. doi: 10.1080/13543784.2021.1995355. Epub 2021 Nov 9. Expert Opin Investig Drugs. 2021. PMID: 34698609 Review.
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J; Cancer Research UK Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee. Workman P, et al. Among authors: mcsheehy pm. J Natl Cancer Inst. 2006 May 3;98(9):580-98. doi: 10.1093/jnci/djj162. J Natl Cancer Inst. 2006. PMID: 16670384 Review.
Role of the microenvironment for radiosensitization by patupilone.
Bley CR, Jochum W, Orlowski K, Furmanova P, Vuong V, McSheehy PM, Pruschy M. Bley CR, et al. Among authors: mcsheehy pm. Clin Cancer Res. 2009 Feb 15;15(4):1335-42. doi: 10.1158/1078-0432.CCR-08-0969. Clin Cancer Res. 2009. PMID: 19228735 Free article.
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Burgenske DM, Talele S, Pokorny JL, Mladek AC, Bakken KK, Carlson BL, Schroeder MA, He L, Hu Z, Gampa G, Kosel ML, Decker PA, Kitange GJ, Schmitt-Hoffmann A, Bachmann F, Vaubel RA, Eckel-Passow JE, Giannini C, McSheehy P, Lane HA, Elmquist WF, Sarkaria JN. Burgenske DM, et al. Among authors: mcsheehy p. Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162. Neuro Oncol. 2022. PMID: 34232318 Free PMC article.
Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models.
El Shemerly M, Zanini E, Lecoultre M, Walker PR, Kellenberger L, Lane HA, McSheehy PMJ. El Shemerly M, et al. Among authors: mcsheehy pmj. Anticancer Drugs. 2023 Oct 1;34(9):1035-1045. doi: 10.1097/CAD.0000000000001480. Epub 2022 Dec 19. Anticancer Drugs. 2023. PMID: 36729099
39 results